A patient developed granulomatosis with polyangiitis (GPA), a type of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), following a long-standing history of systemic lupus ...
The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...
Antimitochondrial antibodies can be detected in patients with systemic lupus erythematosus (SLE) and appear prognostic.
Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...
Objective To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for treatment discontinuation and potential risk factors for subsequent ...
The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.
Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...
In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss diagnostic and treatment gaps in disease management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results